| Name | Title | Contact Details |
|---|
Making advanced diagnostics and adoptive cell therapies more accessible by working from the bottom up via synthetic cells.
Oncobiologics, Inc. has changed its name to Outlook Therapeutics, Inc. Outlook Therapeutics is a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD). ONS-5010 is currently in its first clinical trial, which is being conducted outside of the U.S. and is designed to serve as the first of two adequate and well controlled studies for wet AMD.
Genomenon is an AI-driven genomics company whose mission is to save and improve lives by making genomic information actionable for patients with rare genetic diseases and cancer.
Woodcock Washburn is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tallac Therapeutics is a privately held biopharmaceutical company harnessing the power of innate and adaptive immunity to fight cancer.